Downregulating hypoxia‐inducible factor‐2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma
Open Access
- 6 December 2011
- journal article
- Published by Wiley in Cancer Science
- Vol. 103 (3) , 528-534
Abstract
The hypoxic microenvironment inside solid tumors, including hepatocellular carcinoma (HCC), is a major cause of tumor resistance to chemotherapy. The recently identified hypoxia‐inducible factor (HIF)‐2 executes the hypoxia response. Its expression feature and transcriptional targets indicate a possible dominance of HIF‐2 in regulating genes in HCC. The aim of the present study was to determine whether transfection of siRNA targeting HIF‐2α could enhance the efficacy of doxorubicin, the most commonly used drug in the treatment of HCC. Transfection ofHIF‐2siRNA into human HCC cells downregulated the expression of HIF‐2α, vascular endothelial growth factor (VEGF), transforming growth factor (TGF)‐α, and cyclin D1, but had little effect on the expression of HIF‐1α, fms‐related tyrosine kinase‐1 (Flt‐1), the glucose transporter (GLUT)‐1, and lactate dehydrogenase A (LDHA). Doxorubicin itself only downregulated VEGF expression. Furthermore,HIF‐2siRNA inhibited proliferation, induced cell cycle arrest at the G0/G1phase, and acted synergistically with doxorubicin to inhibit the growth of human HCC cellsin vitro.Transfection ofHIF‐2siRNA also downregulated tumoral expression of HIF‐2α, VEGF, TGF‐α, and cyclin D1in vivo, and acted synergistically with doxorubicin to suppress the growth of HepG2 tumors established in immunodeficient mice by inhibiting cell proliferation, tumor angiogenesis and microvessel perfusion. The results of the present study suggest that targeting HIF‐2α with siRNA warrants investigation as a potential strategy to enhance the efficacy of doxorubicin in the treatment of HCC. (Cancer Sci2012; 103: 528–534)Keywords
This publication has 48 references indexed in Scilit:
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- TGF‐β inactivation and TGF‐α overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancerInternational Journal of Cancer, 2010
- COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesisProceedings of the National Academy of Sciences, 2010
- Endothelial deletion of hypoxia-inducible factor–2α (HIF-2α) alters vascular function and tumor angiogenesisBlood, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Hypoxia-inducible factor-2 regulates vascular tumorigenesis in miceOncogene, 2008
- The role of hypoxia-inducible factors in tumorigenesisCell Death & Differentiation, 2008
- Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancerProceedings of the National Academy of Sciences, 2007
- Hypoxia-inducible factor–2 (HIF-2) regulates hepatic erythropoietin in vivoJournal of Clinical Investigation, 2007
- Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in miceCarcinogenesis, 2007